After meticulous SAR refinement through multiple rounds of chemical modifications the new generation of compounds demonstrated remarkable low picomolar activity towards different cancer cells in vitro. Their potent cytotoxic activity surpasses the cytotoxicity observed in standard-of-care drugs tested within the same cancer model.

The recent innovation study was carried out by Swiss Institute for Quality Testing (SIQT), covering the period from January 1st, 2021, to April 30th, 2023. The analysis focused on the objectively measurable number of patents as the best indication of innovation.

Floratekā€™s innovative approach to development of anti-cancer compounds has been rewarded with outstanding results that will be shared at American Association for Cancer Research (AACR) Annual Meeting in San Diego next year.